Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population. Methods: The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan. Results: Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean class number, 3.4). The most common comedication classes were ESRD-associated medications (94.1%), cardiovascular drugs (69.8%) and antidiabetic drugs (43.2%). ESRD-associated medications were excluded from DDI analysis. Sofosbuvir/velpatasvir/voxilaprevir had the highest frequency of potential contraindicated DDIs (red, 5.6%), followed by glecaprevir/pibrentasvir (4.0%), sofosbuvir/ledipasvir (1.3%), sofosbuvir/velpatasvir (1.3%), and elbasvir/ grazoprevir (0.3%). For potentially significant DDIs (orange, requiring close monitoring or dose adjustments), sofosbuvir/ velpatasvir/voxilaprevir had the highest frequency (19.9%), followed by sofosbuvir/ledipasvir (18.2%), glecaprevir/ pibrentasvir (12.6%), sofosbuvir/velpatasvir (12.6%), and elbasvir/grazoprevir (7.3%). Overall, lipid-lowering agents were the most common comedication class with red-category DDIs to all DAA regimens (n=62), followed by cardiovascular agents (n=15), and central nervous system agents (n=10). Conclusions: HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. Elbasvir/grazoprevir had the fewest potential DDIs, and sofosbuvir/velpatasvir/voxilaprevir had the most potential DDIs.
Abstract
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population. Methods: The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan. Results: Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean class number, 3.4). The most common comedication classes were ESRD-associated medications (94.1%), cardiovascular drugs (69.8%) and antidiabetic drugs (43.2%). ESRD-associated medications were excluded from DDI analysis. Sofosbuvir/velpatasvir/voxilaprevir had the highest frequency of potential contraindicated DDIs (red, 5.6%), followed by glecaprevir/pibrentasvir (4.0%), sofosbuvir/ledipasvir (1.3%), sofosbuvir/velpatasvir (1.3%), and elbasvir/ grazoprevir (0.3%). For potentially significant DDIs (orange, requiring close monitoring or dose adjustments), sofosbuvir/ velpatasvir/voxilaprevir had the highest frequency (19.9%), followed by sofosbuvir/ledipasvir (18.2%), glecaprevir/ pibrentasvir (12.6%), sofosbuvir/velpatasvir (12.6%), and elbasvir/grazoprevir (7.3%). Overall, lipid-lowering agents were the most common comedication class with red-category DDIs to all DAA regimens (n=62), followed by cardiovascular agents (n=15), and central nervous system agents (n=10). Conclusions: HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. Elbasvir/grazoprevir had the fewest potential DDIs, and sofosbuvir/velpatasvir/voxilaprevir had the most potential DDIs.
참고문헌 (43)
- Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study", Lancet Gastroenterol Hepatol, 2, pp.161~176 (2017)
- Yu ML, "Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan", Medicine (Baltimore), 94, pp.e690~ (2015)
- Yang JF, "Viral hepatitis infections in southern Taiwan: a multicenter community-based study", Kaohsiung J Med Sci, 26, pp.461~469 (2010)
- Chen CH, "Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants", J Formos Med Assoc, 106, pp.148~155 (2007)
- Saran R, "US renal data system 2018 annual data report:epidemiology of kidney disease in the United States", Am J Kidney Dis, 73(3 Suppl 1), pp.A7~A8 (2019)
- Jadoul M, "Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients", Kidney Int, 95, pp.939~947 (2019)
- Fabrizi F, "Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?", J Viral Hepat, 19, pp.601~607 (2012)
- Goodkin DA, "Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis", Clin J Am Soc Nephrol, 12, pp.287~297 (2017)
- Söderholm J, "Higher risk of renal disease in chronic hepatitis C patients:antiviral therapy survival benefit in patients on hemodialysis", J Hepatol, 68, pp.904~911 (2018)
- Yu ML, "Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients: a model for prioritization of treatment", Clin Cancer Res, 23, pp.1690~1697 (2017)
- Huang JF, "Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan", Aliment Pharmacol Ther, 25, pp.1029~1037 (2007)
- Huang CF, "Extrahepatic malignancy among patients with chronic hepatitis C after antiviral therapy: a real-world nationwide study on Taiwanese chronic hepatitis C cohort (T-COACH)", Am J Gastroenterol, 115, pp.1226~1235 (2020)
- Omata M, "APASL consensus statements and recommendation on treatment of hepatitis C", Hepatol Int, 10, pp.702~726 (2016)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- Yu ML, "2020 Taiwan consensus statement on the management of hepatitis C:part (I) general population", J Formos Med Assoc, 119, pp.1019~1040 (2020)
- Yu ML, "2020 Taiwan consensus statement on the management of hepatitis C:part (II) special populations", J Formos Med Assoc, 119, pp.1135~1157 (2020)
- Liu CH, "Pegylated interferon-α2a with or without low-dose ribavirin for treatmentnaive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial", Ann Intern Med, 159, pp.729~738 (2013)
- Liu CH, "Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis:a randomised trial", Gut, 64, pp.303~311 (2015)
- Chiu YW, "Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients", Clin J Am Soc Nephrol, 4, pp.1089~1096 (2009)
- Höner Zu Siederdissen C, "Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort", Clin Infect Dis, 62, pp.561~567 (2016)
- Liu CH, "Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan", Aliment Pharmacol Ther, 48, pp.1290~1300 (2018)
- Sicras Mainar A, "Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain", Gastroenterol Hepatol, 42, pp.465~475 (2019)
- Desnoyer A, "Pharmacokinetics, safety and efficacy of a full dose sofosbuvirbased regimen given daily in hemodialysis patients with chronic hepatitis C", J Hepatol, 65, pp.40~47 (2016)
- Borgia SM, "Sofosbuvir", velpatasvir for 12 weeks in hepatitis C virusinfected patients with end-stage renal disease undergoing dialysis, 2019, pp.71, 660~665
- Yu ML, "High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients", J Hepatol, 60, pp.253~259 (2014)
- Huang CF, "Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics", Hepatol Int, 8, pp.224~232 (2014)
- Chang JM, "Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients", Int J Med Sci, 11, pp.436~441 (2014)
- Vermehren J, "Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C", J Clin Virol, 52, pp.133~137 (2011)
- "Interaction charts for directly acting antivirals & ribavirin"[URL]
- "A Drug-Drug, Drug-Herb, and Herb-Herb analysis tool, provided by Wolters Kluwer Clinical Drug Information utilizing Lexicomp clinical content"[URL]
- Ruzicka DJ, "Comorbidities and comedications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016", BMC Infect Dis, 18, pp.237~ (2018)
- Wu MY, "Taiwan renal care system: a learning health-care system", Nephrology (Carlton), 23(Suppl 4), pp.112~115 (2018)
- Louie KS, "The high comorbidity burden of the hepatitis C virus infected population in the United States", BMC Infect Dis, 12, pp.86~ (2012)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- "Sovaldi: prescribing information"[URL]
- "Harvoni: prescribing information"[URL]
- "Epclusa: prescribing information"[URL]
- "Vosevi: prescribing information"[URL]
- "Maviret: prescribing information"[URL]
- Langness JA, "Optimizing hepatitis C virus treatment through pharmacist interventions:identification and management of drug-drug interactions", World J Gastroenterol, 23, pp.1618~1626 (2017)
- Huang CF, "Cure or curd: modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication", Kaohsiung J Med Sci, 36, pp.920~928 (2020)
- García-Agudo R, "‘Real-life’ experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease", Int J Artif Organs, 41, pp.363~370 (2018)
- Zyoud SH, "Use of complementary and alternative medicines in haemodialysis patients: a cross-sectional study from Palestine", BMC Complement Altern Med, 16, pp.204~ (2016)